VANESSA MAGEE: Open Payments
NPI 1760807556 · LOUISVILLE, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,138 in 85 payments from 16 companies in 2025. Trend: 2023 $1,592 · 2024 $1,892 · 2025 $2,138
Food & beverage: $2,104Education: $34
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 12 | $405 |
| GENZYME CORPORATION | 7 | $361 |
| GlaxoSmithKline, LLC. | 15 | $320 |
| Novartis Pharmaceuticals Corporation | 15 | $235 |
| CSL Behring | 7 | $222 |
| Regeneron Healthcare Solutions, Inc. | 5 | $101 |
| Amgen Inc. | 5 | $98 |
| BioCryst US Sales Co., LLC | 4 | $87 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $82 |
| PFIZER INC. | 2 | $47 |
Products named: DUPIXENT, NUCALA, TEZSPIRE, FASENRA, Hizentra, Rhapsido, ORLADEYO, TAKHZYRO.
Industry payments across KY — which companies pay providers there.
